Metastatic Stage IV (D) Prostate Cancer


Xgeva Approved for Patients with Bone Metastases (11-30-2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with... Continue Reading

Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer (10-20-2008)

Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer Excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were... Continue Reading